 AML1/ETO results from the t(8;21) associated with 12%-15% of acute myeloid leukemia.     ///    Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity..     ///    "We demonstrated that a single amino acid substitution that disrupts the interaction between the MYND domain and the SMRT peptide attenuated AML1/ETO's effects on proliferation, differentiation, and gene expression.. "    ///    The AML1/ETO MYND domain mediates interactions with the corepressors SMRT and N-CoR and contributes to AML1/ETO's ability to repress proliferation and differentiation of primary bone marrow cells as well as to enhance their self renewal in vitro. 